Asset Acquisition, Consideration Transferred, Equity Interest, Share Issued, Number of Shares

No definition available.

Name:	txg_AssetAcquisitionConsiderationTransferredEquityInterestShareIssuedNumberOfShares
Namespace Prefix:	txg_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

Asset Acquisition, Contingent Consideration, Attributable To Sellers

+ References

No definition available.

+ Details

Name:	txg_AssetAcquisitionContingentConsiderationAttributableToSellers
Namespace Prefix:	txg_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Asset Acquisition, Contingent Consideration, Range of Outcomes, Maximum, Amount

+ References

No definition available.

+ Details

Name:	txg_AssetAcquisitionContingentConsiderationRangeOfOutcomesMaximumAmount
Namespace Prefix:	txg_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Asset Acquisition, Gain (Loss) Contingent Consideration, Change In Fair Value Disclosure

+ References

No definition available.

+ Details

Name:	txg_AssetAcquisitionGainLossContingentConsiderationChangeInFairValueDisclosure
Namespace Prefix:	txg_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Payments For Asset Acquisitions

+ References

No definition available.

+ Details

Name:	txg_PaymentsForAssetAcquisitions
Namespace Prefix:	txg_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of acquirer's equity interest issued and issuable as part of consideration transferred in asset acquisition.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 50
-Name Accounting Standards Codification
-Section 25
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480060/805-50-25-1

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 50
-Name Accounting Standards Codification
-Section 30
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480027/805-50-30-1

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 50
-Name Accounting Standards Codification
-Section 30
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480027/805-50-30-2

+ Details

Name:	us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-4

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 50
-Name Accounting Standards Codification
-Section 15
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480123/805-50-15-3

+ Details

Name:	us-gaap_AssetAcquisitionLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_AssetAcquisitionAxis=txg_ScaleBioScienceInc.AcquisitionMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementScenarioAxis=srt_ScenarioForecastMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Asset Acquisition - Additional Information (Details) - USD ($) $ in Thousands		2 Months Ended	3 Months Ended		9 Months Ended
	Aug. 11, 2025	Sep. 30, 2025	Mar. 31, 2026	Sep. 30, 2025	Sep. 30, 2025	Sep. 30, 2024
Asset Acquisition [Line Items]
Change in fair value					$ (1,135)	$ 0
Scale BioScience Inc. Acquisition
Asset Acquisition [Line Items]
Cash consideration	$ 9,200
Equity consideration	$ 13,500
Equity consideration, number of share issued (in shares)	1,099,992
Milestone payment				$ 30,000
Contingent consideration attributable to sellers	$ 22,400				22,378
Change in fair value		$ (1,100)		$ (1,100)	$ (1,135)
Scale BioScience Inc. Acquisition \| Forecast
Asset Acquisition [Line Items]
Cash consideration			$ 20,000